Supratentorial Malignant Gliomas: Risk Patterns and Therapy

Phase II study of fotemustine in recurrent supratentorial malignant gliomas.

38 adults with recurrent supratentorial malignant gliomas, including glioblastoma multiforme (21), anaplastic astrocytomas (9), probably transformed low-grade astrocytomas (6), pinealoblastoma (1) and non-metastatic tumour of unknown histology (1), were treated with fotemustine 100 mg/m2 intravenously every week for 3 consecutive weeks followed by a 5-week rest period. Maintenance treatment con...

Gene Therapy for Malignant Gliomas

Retroviruses are enveloped RNA viruses that possess the ability to integrate into the host cell genome by transcribing DNA from their RNA template via viral reverse transcriptase. The transcribed viral DNA is then integrated into the host cell genome nonspecifically. There is relative specificity for tumors because, except for lentiviruses, retroviral DNA preferentially integrates into the geno...

Current and Future Gene Therapy for Malignant Gliomas

Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene therapy is expected to be an effective and possibly curative treatment. Many gene therapeutic approach...

Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas

Disease progression patterns of bevacizumab responders with recurrent malignant gliomas

Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who responded to BEV therapy. From August 2011 to November 2015, 24 patients (18 glioblastoma cases an...